Platinum-based chemotherapeutics are a class of DNA-damaging agents, including cisplatin, carboplatin and oxaliplatin; these have established efficacy in breast cancer treatment.157In vitro studies have indicated that combining TRAIL and cisplatin significantly increased BCSC death compared to other standard of care treatments in TNBC cell lines.158 The study showed that treatment with TRAIL and cisplatin inhibited Wnt1-mediated signaling and expression of cyclin D1, as well as the phosphorylation of β-catenin. This evidence concerns the gene TNFSF10 and breast cancer.